Icure Pharmaceutical (XKRX:175250) FCF Margin % : -31.27% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Icure Pharmaceutical's Free Cash Flow for the three months ended in Mar. 2024 was ₩-4,984 Mil. Icure Pharmaceutical's Revenue for the three months ended in Mar. 2024 was ₩15,938 Mil. Therefore, Icure Pharmaceutical's FCF Margin % for the quarter that ended in Mar. 2024 was -31.27%.

As of today, Icure Pharmaceutical's current FCF Yield % is -21.23%.

The historical rank and industry rank for Icure Pharmaceutical's FCF Margin % or its related term are showing as below:

XKRX:175250' s FCF Margin % Range Over the Past 10 Years
Min: -118.99 Med: -36.53 Max: 1.76
Current: -27.24

During the past 10 years, the highest FCF Margin % of Icure Pharmaceutical was 1.76%. The lowest was -118.99%. And the median was -36.53%.

XKRX:175250's FCF Margin % is ranked worse than
80.18% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 0.085 vs XKRX:175250: -27.24

Icure Pharmaceutical FCF Margin % Historical Data

The historical data trend for Icure Pharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical FCF Margin % Chart

Icure Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-118.99

-44.00

-51.23

-29.05

-28.42

Icure Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-35.65	-23.04	-31.82	-21.15	-31.27

Competitive Comparison of Icure Pharmaceutical's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icure Pharmaceutical's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's FCF Margin % falls into.

Icure Pharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Icure Pharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16145.626	/	56806.335
	=	-28.42 %

Icure Pharmaceutical's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4984.174	/	15937.952
	=	-31.27 %

Icure Pharmaceutical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical (XKRX:175250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » FCF Margin %

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical (XKRX:175250) Headlines

No Headlines